Timeline Of Pharma Provisions In Health Care Reform
Executive Summary
This chart gives a look at when provisions affecting pharmaceutical companies - either directly, by expanding the market of insured individuals or by making changes to government prescription drug programs - will begin to take effect (see chart: "1Timeline Of Pharma Provisions In Health Care Reform").
You may also be interested in...
"The Pink Sheet" – Most Notable Stories Of 2010
While industry mega-mergers occupied readers in 2009, the focus in 2010 shifted toward several evolving policy concerns and their impact on company strategy. Among these, more companies are looking at the opportunity for biosimilars created by the health care reform law's provision of a legal framework for product approval. But early analyses suggest that there is still a lot of work to do as FDA develops a guideline for industry on an abbreviated approval pathway.
"The Pink Sheet" – Most Notable Stories Of 2010
While industry mega-mergers occupied readers in 2009, the focus in 2010 shifted toward several evolving policy concerns and their impact on company strategy. Among these, more companies are looking at the opportunity for biosimilars created by the health care reform law's provision of a legal framework for product approval. But early analyses suggest that there is still a lot of work to do as FDA develops a guideline for industry on an abbreviated approval pathway.
Chart: Timeline Of Pharma Provisions In Health Care Reform
It is arranged in seven sections, with provisions in each arranged chronologically. If the date is listed as "upon enactment," it means no date was specified in the statute; however, in many cases, regulatory agencies may need to issue guidance or regulations before the provision can be implemented. The information is based on the two health care reform bills: H.R. 3590, which contains the bulk of the reform language, passed the Senate in December, passed the House March 21, and was signed into law March 23; and subsequent fixes in the budget reconciliation bill, H.R. 4872, which cleared the House March 21 and Senate March 25, and the president was expected to sign March 30. The chart also borrows from a comparison chart of pharma provisionsin the two bills by Ian Spatz of Manatt, Phelps & Phillips.